Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | KDM5A | P29375 | 3/20 | 0.52 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 9/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739280 | 0.88 | PTPN1 (0.59) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL7564914 | 0.83 | PTPN1 (0.53) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL25389924 | 0.79 | EYA3 (0.82) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL1287970 | 0.78 | EYA3 (1.00) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL11846804 | 0.76 | EYA3 (0.63) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL28849127 | 0.76 | EYA3 (0.81) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL11851343 | 0.75 | EYA3 (0.72) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL27992957 | 0.75 | EYA3 (0.80) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL5419199 | 0.75 | EYA3 (0.93) | EYA3PTPN1TTRNR1H4KDM5A | |
| SCHEMBL30768209 | 0.75 | EYA3 (0.93) | EYA3PTPN1TTRNR1H4KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | EYA3 3536/4885PTPN1 178/4885TTR 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.